These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 16429658

  • 1. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H, Lan O, Poulain JE, Comenducci A.
    Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, ARIA3001, ARIA3002 and ARIB3003 Study Investigators.
    Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [Abstract] [Full Text] [Related]

  • 3. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R.
    Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
    [Abstract] [Full Text] [Related]

  • 4. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
    Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R.
    Prostate Cancer Prostatic Dis; 2007 Oct; 10(2):149-54. PubMed ID: 17189955
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
    Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS.
    BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
    [Abstract] [Full Text] [Related]

  • 7. Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.
    Ravish IR, Nerli RB, Amarkhed SS.
    Arch Androl; 2007 Aug; 53(1):17-20. PubMed ID: 17364459
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS.
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [Abstract] [Full Text] [Related]

  • 11. Finasteride for benign prostatic hyperplasia.
    Hasinski S, Miller JL, Rose LI.
    Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
    [Abstract] [Full Text] [Related]

  • 12. [Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: a randomized, double-blind, placebo-controlled, parallel-group, dose response study].
    Tsukamoto T, Endo Y, Narita M.
    Hinyokika Kiyo; 2009 Apr; 55(4):209-14. PubMed ID: 19462826
    [Abstract] [Full Text] [Related]

  • 13. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group.
    J Androl; 1991 Apr; 12(6):372-5. PubMed ID: 1722792
    [Abstract] [Full Text] [Related]

  • 14. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
    Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO.
    Clin Pharmacol Ther; 1998 Dec; 64(6):636-47. PubMed ID: 9871428
    [Abstract] [Full Text] [Related]

  • 15. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M, Fleshner NE, Finelli A, Zlotta AR.
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
    [Abstract] [Full Text] [Related]

  • 16. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    Bartsch G, Rittmaster RS, Klocker H.
    Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
    [Abstract] [Full Text] [Related]

  • 17. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 18. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
    van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF, Schalken JA.
    Prostate; 2009 Nov 01; 69(15):1624-34. PubMed ID: 19588525
    [Abstract] [Full Text] [Related]

  • 19. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
    Dolder CR.
    Ann Pharmacother; 2006 Apr 01; 40(4):658-65. PubMed ID: 16569804
    [Abstract] [Full Text] [Related]

  • 20. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M, Ramsdell J, Young J, McNicholas T.
    J Urol; 2006 Sep 01; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.